Loading
Defined EGFR resistance mechanisms in lung cancer and now leads early-detection research including the Sybil AI lung-risk model.
Lecia V. Sequist is Director of the Center for Innovation in Early Cancer Detection and Landry Family Professor of Medicine at Massachusetts General Hospital Cancer Center. She is a thoracic oncologist known for defining EGFR resistance mechanisms in lung cancer, leading the 2011 analysis of resistance to EGFR inhibitors and early osimertinib development. Her selected papers report the genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors, and Sybil, a validated deep learning model that predicts future lung cancer risk from a single low-dose chest CT scan. She now directs MGH's early cancer detection centre and works on low-dose CT screening and AI risk models.
| Title | Journal | Year |
|---|---|---|
| Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors | Science Translational Medicine | 2011 |
| Sybil: a validated deep learning model to predict future lung cancer risk from a single low-dose chest computed tomography | Journal of Clinical Oncology | 2023 |
It is the practical guide to what to do after transformation: treat it as small-cell lung cancer with platinum and etoposide, expect central nervous system disease, and do not expect a checkpoint inhibitor to help.
It is the study that made multiplex testing standard practice in lung adenocarcinoma, by showing both that most tumours have a driver and that finding it changes what patients receive.
The case for re-biopsy at progression, for treating resistance as a diagnosis rather than an endpoint, and for the idea of a drug holiday. It is also the origin of resistance-directed sequencing: what you give next should depend on what the tumour became.
The template for every driver mutation since: find the responders, sequence them, and give the drug only to people whose tumour carries the lesion it was built for. Gefitinib had been close to abandonment on the strength of unselected trials.
Shares Massachusetts General Hospital Cancer Center, EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer.
Shares Science Translational Medicine, Massachusetts General Hospital Cancer Center, AI in radiology.
Shares Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer.
Shares Science Translational Medicine, Massachusetts General Hospital Cancer Center, EGFR.
Shares Low-dose CT lung screening, AI in radiology, Non-small-cell lung cancer.
Shares Low-dose CT lung screening, AI in radiology, Non-small-cell lung cancer.
Shares Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors, EGFR-mutated non-small-cell lung cancer, EGFR.
Shares Low-dose CT lung screening, AI in radiology, Non-small-cell lung cancer.